Introduction {#S1}
============

Salivary gland dysfunction and the associated hyposalivation are serious clinical problems that impact millions of people ([@B15]; [@B258]; [@B289]). Saliva plays a crucial role in maintaining oral homeostasis by aiding in taste perception and digestion, protecting and lubricating oral tissues, maintaining the integrity of tooth enamel and sustaining the oral microbiome ([@B73]). In addition to its physiological roles, saliva contains a plethora of biomarkers and is easy to access allowing clinicians to utilize saliva as a non-invasive diagnostic material to monitor patient health ([@B60]). Human saliva is increasingly being used to perform screening and risk assessment for systemic diseases, such as HIV, cancer, infections and cardiovascular disorders, demonstrating saliva's extensive clinical potential ([@B229]). Adequate saliva production is essential for maintaining quality of life and salivary gland dysfunction leads to dry mouth, oral bacterial and yeast infections, dental caries and speech problems ([@B52]; [@B197]).

Hyposalivation and xerostomia (i.e., dry mouth) can present in an iatrogenic manner as side effects of over 400 medications, including antidepressants, antipsychotics, opioids, antihistamines, and others ([@B102]). Although often transient and reversible, iatrogenic xerostomia contributes to patient non-adherence to medication regimens leaving underlying pathologies untreated. Two common pathophysiological causes of salivary gland dysfunction in humans are Sjögren's syndrome (SS), an autoimmune disease characterized by xerostomia, autoantibody production and chronic lymphocytic infiltration of the salivary glands (i.e., sialadenitis), and radiotherapy-induced dysfunction where salivary glands sustain collateral damage following γ-radiation to treat head and neck tumors ([@B250]; [@B190]). In both cases, damage to the salivary parenchyma and the failure to repair saliva-producing salivary acinar epithelium contribute to glandular dysfunction. Current therapies for salivary gland dysfunction are primarily focused on symptom management using muscarinic receptor agonists (i.e., pilocarpine or cevimeline) to stimulate saliva flow from residual salivary epithelium or through the topical use of artificial saliva ([@B262]). While these treatments can provide some relief to patients, they are relatively ineffective because of their transient nature and failure to address the underlying inflammatory and degenerative processes that initiate and sustain glandular tissue damage. Therefore, a better understanding of the pathophysiology of salivary gland dysfunction is crucial to developing novel therapeutic approaches for this serious medical problem.

Purinergic receptors for extracellular nucleosides (i.e., adenosine) or nucleotides (i.e., ATP, ADP, UTP, UDP, and UDP-glucose) mediate numerous physiological processes, including platelet aggregation, neurotransmission, bone remodeling, and inflammatory, and immune responses ([@B84]; [@B236]; [@B138]; [@B213]; [@B325]). In exocrine tissues, such as salivary gland, lacrimal gland and pancreas, purinergic receptor-mediated ion fluxes and cross-talk with muscarinic receptor signaling have been suggested to modulate secretory function ([@B227]; [@B44]; [@B122]). Whereas intracellular nucleotides are well-known for their role in metabolism and enzyme function, it wasn't until the 1970s that plasma membrane receptors were postulated to respond to extracellular nucleotides, including ATP and ADP, and were suggested to be responsible for non-cholinergic, non-adrenergic neurotransmission ([@B42]; [@B40]). Under normal conditions, extracellular nucleotides are present at minute concentrations due to the presence of ectonucleotidases ([@B267]; [@B359]). However, under pathological conditions nucleotides can accumulate in the extracellular space at abnormally high concentrations, whereupon they activate local purinergic receptors in an autocrine or paracrine manner ([@B78]). The purinergic receptor family is subclassified into P1 adenosine receptors (i.e., A~1~, A~2A~, A~2B~, and A~3~) ([@B249]) or P2 nucleotide receptors. The P2 receptor family is further classified into metabotropic P2Y receptors (i.e., P2Y~1,2,4,6,11--14~) and ionotropic P2X receptors (i.e., P2X1-7) ([@B1]; [@B115]).

Pharmacological agonists and antagonists targeting purinergic receptors have gained widespread clinical interest and undergone clinical trials ([@B41]). P2X7 receptor (P2X7R) antagonists have been previously investigated in phase 2 clinical trials for treatment of inflammatory and autoimmune diseases, including chronic obstructive pulmonary disorder, rheumatoid arthritis and Crohn's disease ([@B14]; [@B152]). Recent advances in the development of neuro-permeable P2X7R antagonists have stimulated interest in the use of these compounds to treat neuroinflammatory and neuropsychiatric disorders ([@B62]; [@B43]; [@B29]). The P2X3 receptor (P2X3R) contributes to hypersensitivity of lung afferent sensory fibers that mediate cough initiation and phase 2 clinical trials have demonstrated that the P2X3R antagonist gefapixant (AF-219) reduces refractory chronic cough in afflicted patients by 75% ([@B335]; [@B2]). Follow-up phase 3 clinical trials are currently underway to validate the use of gefapixant for treatment of refractory chronic cough ([@B208]).

Due to its ability to stimulate water transport across epithelial cell membranes following activation of calcium-dependent chloride channels, the P2Y~2~ receptor (P2Y~2~R) agonist diquafosol has undergone human clinical trials for the treatment of dry eye disease (DED) and is currently approved for human use in Japan and South Korea under the trade name Diquas ([@B310]; [@B306]; [@B159]). A similar P2Y~2~R agonist, denufosol, improved lung function relative to placebo in cystic fibrosis patients during phase 2 clinical trials, but failed to achieve its primary endpoints during phase 3 follow-up trials ([@B3]). Notably, the FDA-approved anti-coagulant Plavix (clopidogrel), a P2Y~12~ receptor (P2Y~12~R) antagonist, was the 2^nd^ most prescribed drug in the world in 2010 and is currently on the World Health Organization's List of Essential Medicines ([@B314]; [@B157]). However, the therapeutic potential of targeting purinergic receptors has not been well-investigated in the context of human salivary dysfunction. In the salivary glands, several purinergic receptors are expressed and upregulated under pathological conditions, including SS ([@B273]; [@B23]), where their activation mediates inflammatory and immune responses ([@B22]; [@B154]), as well as cell repair mechanisms ([@B89]). In this review, we summarize the role of purinergic receptors in salivary gland function and highlight their potential as novel therapeutic targets to treat salivary gland dysfunction.

The Role of P2 Receptors in Salivary Gland Function {#S2}
===================================================

The importance of saliva, as noted above, is clearly exemplified in individuals suffering from salivary gland hypofunction ([@B52]; [@B15]; [@B197]). In humans, whole unstimulated saliva is formed from the combined secretions of three pairs of major salivary glands, the submandibular (∼65%), parotid (∼20%) and sublingual (∼7%), along with numerous minor glands spread throughout the oral cavity that produce the remainder of saliva (\<10%) ([@B130]; [@B75]; [@B255]). Upon stimulation, the parotid glands contribute the majority of total salivary secretions ([@B130]; [@B75]; [@B255]). Three basic cell types comprise the salivary glands: acinar epithelial cells that secrete the majority of the water and electrolytes in saliva, ductal cells that modify the electrolyte concentrations in the primary fluid and myoepithelial cells that provide contractile support for acinar cells ([@B191]; [@B198]; [@B75]; [@B255]). Salivary acinar cells are either serous or mucous, whereas ductal cells are classified as intercalated, striated or excretory and the distribution of these cell types is dependent on species and type of gland ([@B198]; [@B75]; [@B255]). Along with the formation and modification of saliva, acinar and ductal cells also secrete important proteins, e.g., amylase and mucins from acinar cells ([@B32]; [@B100]), kallikrein from ductal cells ([@B341]) and growth factors from both cell types ([@B192]), that are integral in maintaining the health of the oral cavity ([@B255]). As shown in [Figure 1](#F1){ref-type="fig"}, saliva formation is initiated in acinar cells by agonist-induced increases in intracellular Ca^2+^ levels, \[Ca^2+^\]~i~, that induce the opening of apical Ca^2+^-dependent Cl^--^ channels and basolateral Ca^2+^-dependent potassium channels, allowing Cl^--^ efflux into the luminal compartment and K^+^ efflux into the basolateral compartment to maintain membrane potential. The negative electrochemical gradient generated by increased luminal Cl^--^ levels is compensated by the influx of Na^+^ ions across tight junctions into the lumen leading to Na^+^Cl^--^ accumulation followed by water movement through water channels, predominately aquaporin-5 ([@B186]), thus forming saliva in its primary isotonic form. As saliva flows through the salivary gland ducts, electrolyte modification occurs, where Na^+^ and Cl^--^ ions are exchanged for K^+^ and HCO$_{3}^{-}$ ions by ductal cells, creating saliva in its final hypotonic form ([@B191]; [@B198]; [@B165]; [@B11]; [@B255]). Several types of Ca^2+^ mobilizing receptors are expressed on acinar cells (i.e., muscarinic, α-adrenergic, substance P), however, stimulation of the G~q~ protein-coupled M3 muscarinic receptor (M~3~R) subtype by acetylcholine is accepted as the main receptor signaling pathway that promotes the increases in \[Ca^2+^\]~i~ necessary to enhance fluid secretion. Protein secretion from acinar and ductal cells is predominately mediated by activation of the β-adrenergic receptor (β-AR) and subsequent increases in cAMP ([@B198]; [@B255]). In addition to the canonical M~3~R and β-AR pathways, a mechanism of non-cholinergic, non-adrenergic-mediated salivary flow exists ([@B87]; [@B86]; [@B198]). Because purinergic receptor activation can result in an increase in \[Ca^2+^\]~i~ in salivary gland cells, purinergic receptor-mediated saliva production may contribute to this non-canonical pathway ([@B322]; [@B198]; [@B17]; [@B30]).

![Salivary gland acinar and ductal cells contribute to saliva formation. **(A)** Activation of type 3 muscarinic receptors (M~3~R) by acetylcholine (Ach) increases release of calcium from intracellular stores and subsequent opening of the apical Ca^2+^-dependent chloride channel transmembrane member 16A (TMEM16A; also known as anoctamin-1) and the basolateral Ca^2+^-dependent potassium channels MaxiK (*Kcnma1*) and IK1 (*Kcnn4*), allowing Cl^--^ efflux into the luminal compartment and K^+^ efflux into the basolateral compartment to maintain membrane potential. The combined actions of the Na^+^/K^+^/2 Cl^--^ cotransporter NKCC1, the Na^+^/H^+^ exchanger NHE1 and the Cl^--^/HCO$_{3}^{-}$ anion exchanger AE2 maintain the pool of intracellular Cl^--^ whereas the Na^+^/K^+^ ATPase generates the cellular Na^+^ and K^+^ gradients. Sodium influx down the negative electrochemical gradient into the luminal compartment is followed by water through aquaporin 5 (AQP5) water channels generating primary isotonic saliva. Modification of saliva by ductal cells involves exchanging sodium and chloride for potassium and bicarbonate through the combined actions of epithelial Na^+^ channels (ENaC), cystic fibrosis transmembrane conductance regulator (CFTR) channels, MaxiK channels and perhaps Cl^--^/HCO$_{3}^{-}$ exchangers. The resulting hypotonic saliva is then secreted through ducts into the oral cavity. Functional P2X4, P2X7, P2Y~1~, and P2Y~2~ receptor expression has been demonstrated in both acinar and ductal cells where they may regulate secretory functions through nucleotide-induced Ca^2+^ signaling and modulation of membrane ion conductance. Available evidence suggests that P2X7 and P2Y~2~ receptors exist on both apical and basolateral membranes while P2X4 receptors are restricted to the basolateral compartment and P2Y~1~ receptor localization is undetermined. Importantly, P2 receptor expression in salivary gland tissue varies depending on species, isolation/culture methods and the presence of inflammatory stimuli, making definitive localization inexact. **(B)** Acinar (white) and ductal (yellow) cells outlined in a hematoxylin and eosin-stained section of a female C57BL/6 mouse submandibular gland.](fphar-11-00222-g001){#F1}

In other exocrine tissues, purinergic receptor signaling has been shown to modulate secretory function of acinar and ductal cells through the induction of cellular ion fluxes and cross-talk with cholinergic signaling pathways ([@B44]; [@B122]). In the pancreas, acinar cells have little functional response to exogenously applied nucleotides ([@B228]), whereas ductal cells that secrete bicarbonate and isotonic fluid express numerous functional P2X and P2Y receptors ([@B117]). In response to stimulation by acetylcholine or secretin, pancreatic ductal cell secretion is mediated by the opening of luminal Cl^--^ channels, including Ca^2+^-activated Cl^--^ channels, as well as basolateral K^+^ channels to maintain driving force for ion transport ([@B226]). Therefore, the finding that extracellular ATP and UTP induce increases in \[Ca^2+^\]~i~ and modulate whole cell Cl^--^ and K^+^ conductance suggests a role for purinergic receptors in secretory regulation of pancreatic ductal cells ([@B61]; [@B117]; [@B360]). Furthermore, studies have shown that cholinergic agonists induce ATP release from pancreatic acinar cells ([@B294]), as well as parotid and lacrimal gland cell preparations ([@B227]; [@B71]), further supporting a role for purinergic signaling in the regulation of exocrine secretory function. In rat lacrimal gland acinar cells, extracellular nucleotide-induced protein secretion and \[Ca^2+^\]~i~ increases were inhibited by the cholinergic antagonist atropine ([@B71]) whereas in rat parotid acinar cells extracellular nucleotides attenuated acetylcholine-induced \[Ca^2+^\]~i~ increases ([@B147]; [@B101]). Although the nature of purinergic and cholinergic signaling interaction differs between exocrine tissues, these studies highlight the likely regulatory role of purinergic receptors in exocrine secretory function.

Ten years prior to the initial cloning and identification of P2 receptors, [@B104] presented the first evidence of P2 receptor activation in salivary glands. His studies demonstrated that ATP evoked a marked increase in membrane conductance, K^+^ efflux and amylase secretion in the mouse parotid gland, events similar to cholinergic- and adrenergic-mediated saliva secretion ([@B198]; [@B255]). [@B195] showed that high extracellular ATP concentrations increased \[Ca^2+^\]~i~ in rat parotid acinar cells, the signaling response that promotes saliva production ([@B198]). Additional studies by the same group and others determined that the large ATP-induced rise in \[Ca^2+^\]~i~ was due to the influx of extracellular Ca^2+^ through a non-selective cation channel activated by the fully ionized form of ATP (i.e., ATP^4--^) ([@B293]; [@B80]; [@B194]). The order of agonist potency for channel activation in these studies was determined to be BzATP \> ATP \> ATPγS = 2MeSATP; thus, the receptor was classified as P~2Z,~ now known as the P2X7 receptor (P2X7R) ([@B293]; [@B80]; [@B194]). Thus, a physiological role for ATP in the Ca^2+^-dependent formation of saliva was proposed, particularly since ATP was known to be released as a co-transmitter from activated sympathetic and parasympathetic nerve fibers ([@B329]; [@B225]). During the ensuing years, especially following the cloning, expression and identification of cDNAs for a variety of P2 receptors in the early 1990s ([@B184]; [@B333]; [@B220]; [@B298]), several groups confirmed the expression of P2X7R in salivary gland cells and also identified and functionally characterized the ionotropic P2X4 receptor (P2X4R) and metabotropic P2Y receptors, P2Y~1~R and P2Y~2~R, in these cells ([@B320]).

The P2X7R is a 595 amino acid protein that includes two transmembrane domains, intracellular carboxy and amino termini and a bulky hydrophilic extracellular loop with a cysteine rich region that forms disulfide bridges ([@B193]). It shares 40--50% amino acid homology with the other P2X receptors, but is structurally distinct in that its C-terminal tail extends for an additional 100--200 amino acids ([@B223]; [@B4]; [@B291]). The P2X7R is activated by high extracellular ATP (eATP) concentrations (\>100 μM) with brief stimulation (10--30 s) causing the depolarization of the plasma membrane due to the opening of a membrane cation channel that promotes the influx of Na^+^ and Ca^2+^ and the efflux of K^+^ ([@B336], [@B337]; [@B4]). Sustained P2X7R activation induces the opening of a pore permeable to hydrophilic molecules up to 900 Da, and promotes production of reactive oxygen species (ROS), NLRP3 inflammasome-dependent IL-1β release, extensive plasma membrane blebbing and ultimately cell death ([@B336], [@B337]; [@B343]; [@B81]; [@B108]; [@B154]). The P2X7R is widely expressed in diverse tissues, including hematopoietic cells ([@B97]), neurons ([@B202]), glia ([@B295]; [@B148]), bone ([@B5]), muscle ([@B94]), endothelium ([@B111]), epithelium ([@B343]), and immune cells ([@B98]). In the exocrine pancreas, P2X7Rs have been shown to be primarily expressed in pancreatic ductal cells where they may contribute to secretory regulation through induction of cation fluxes and interaction with cholinergic signaling ([@B227]; [@B44]). Similarly, in lacrimal glands P2X7Rs mediate \[Ca^2+^\]~i~ increases, ERK1/2 activation, protein secretion and modulate both cholinergic and adrenergic receptor signaling pathways ([@B124]; [@B71], [@B72]). After its initial characterization in rat parotid acinar cells ([@B195]; [@B106]), P2X7R expression and function were reported to promote increases in \[Ca^2+^\]~i~ in rat submandibular acinar cells ([@B166]; [@B8]), murine parotid ([@B171]; [@B265]; [@B31]) and submandibular acinar cells ([@B215]) and human parotid acinar cells ([@B36]).

In addition to numerous studies defining its role in mediating inflammatory and immune responses in disease models ([@B271]; [@B47]; [@B353]), including those pertaining to salivary glands ([@B343]; [@B154]), there is evidence that P2X7Rs regulate salivary secretory function ([@B215]; [@B227]; [@B252]). Along with its ability to increase \[Ca^2+^\]~i~ due to calcium influx, P2X7R activation has been shown to inhibit mobilization of intracellular Ca^2+^ induced by muscarinic or substance P receptor agonists in rat submandibular acinar cells ([@B133]; [@B199]) and cholinergic mobilization of \[Ca^2+^\]~i~ was significantly increased in parotid acinar cells prepared from P2X7R-null (P2X7R^--/--^) mice ([@B227]). The mechanism of this inhibition is still unclear, but it does not appear to be due to interference with binding of the autonomic agonists to their receptors ([@B133]). This observation was corroborated in an *ex vivo* murine submandibular gland (SMG) preparation, where co-stimulation with ATP and muscarinic receptor agonists had an inhibitory effect on the gland's saliva production ([@B215]). Further, in glands prepared from P2X7R^--/--^ mice the inhibitory effect of ATP on carbachol-induced saliva secretion was abolished, suggesting an inhibitory role for P2X7Rs in saliva production ([@B215]). However, in this same study ATP or BzATP alone evoked fluid secretion in a time-dependent manner that was greatly reduced in glands from P2X7R^--/--^ mice, whereas carbachol alone induced similar saliva secretion in wild type and P2X7R^--/--^ glands. Similarly, another study found no significant difference in cholinergic-mediated whole saliva secretion in P2X7R^--/--^ mice compared to wild type ([@B251]). In contrast, [@B227] found that cholinergic-mediated whole saliva secretion was significantly decreased in P2X7R^--/--^ mice, as compared to wild type mice, and this was particularly evident in male mice. While the reasons for the disparities among these studies are unclear, they may be due to differences in the type of saliva collected (i.e., whole saliva vs. saliva from specific glands), methods of induction of saliva secretion, tissue specificity, sex, or mouse strain.

The P2X7R is also expressed in rat ([@B166]; [@B9]) and mouse salivary ductal cells ([@B171]; [@B251]; [@B215]), suggesting participation in the modification of the electrolyte content of saliva. Studies indicate no difference in \[Na^+^\] or \[Cl^--^\] in muscarinic agonist-induced whole saliva secreted in wild type compared to P2X7R^--/--^ mice, however the \[K^+^\] was elevated in P2X7R^--/--^ mouse whole saliva ([@B251]). Since the majority of the K^+^ in saliva originates from ductal cells, it has been hypothesized that ATP released from acinar cells during exocytosis stimulates ductal P2X7Rs that regulate the activity of K^+^ channels located on the apical membrane ([@B179]; [@B30]). In addition to K^+^ modification, activation of P2X7Rs in ductal cells increases phospholipase A2-dependent secretion of arachidonic acid, a precursor of prostaglandin E2 (PGE~2~), and kallikrein ([@B9]) into saliva ([@B239]). Interestingly, cell lines of salivary origin exhibit low expression and function of P2X7R, which are enhanced following DNA demethylation ([@B287]).

Another P2X ionotropic receptor expressed in salivary acinar and ductal cells is the P2X4R ([@B322]). Unlike the P2X7R's requirement for activation by high eATP concentrations, P2X4Rs have nanomolar affinity for ATP ([@B224]; [@B299]) and were initially found to regulate the biphasic response to ATP in rat parotid gland cells ([@B194]). The P2X4R is widely expressed in a variety of cell types, e.g., neurons and microglia ([@B121]), epithelium ([@B50]), and endothelium ([@B185]), and P2X4R expression in microglia is notable for the key role it plays in mediating neuropathic pain ([@B139]). Although RT-PCR analysis has identified P2X4R expression in pancreatic acinar and ductal cells ([@B183]; [@B228]) and lacrimal gland acinar cells ([@B123]; [@B149]), its functional role in exocrine tissues remains largely unexplored. Physical interactions between P2X4Rs and P2X7Rs have been demonstrated, although the nature of this interaction remains controversial ([@B163]). Some studies suggest that P2X4R and P2X7R subunits form heteromeric channels ([@B114]; [@B272]), while others conclude that P2X4 and P2X7 receptors interact in their respective homotrimeric form ([@B221]; [@B35]; [@B12]). Furthermore, P2X4R expression has been localized to lysosomal membranes, whereas P2X7Rs primarily reside at the plasma membrane ([@B114]; [@B128]). Nevertheless, studies have also demonstrated functional evidence for P2X4R/P2X7R interactions ([@B114]; [@B150]; [@B245]). In salivary epithelium, P2X4Rs modulate P2X7R-mediated ion flow and ethidium bromide dye uptake ([@B50]), suggesting a functional interaction that regulates physiological processes, including plasma membrane ion channel function and pore formation. Importantly, the interaction between these two purinergic receptors results in a decreased sensitivity to ATP, as compared to the P2X4R or P2X7R alone, suggesting the formation of heteromeric channels with novel functional and pharmacological properties ([@B50]).

While the contribution of P2X4R activation to physiological saliva production has not been explored, *ex vivo* murine SMG preparations from P2X7R^--/--^ mice exhibit weak ATP-induced saliva secretion that could be attributed to P2X4R activation ([@B215]). As seen previously with muscarinic or adrenergic receptor activation ([@B25]; [@B349]; [@B308]; [@B37]), co-stimulation of β-adrenergic receptors and P2X7Rs or P2X4Rs enhanced the influx of Ca^2+^ in mouse parotid acinar cells, as compared to activation of either receptor alone ([@B30]). In contrast, studies using human parotid acinar cells found this co-stimulatory effect only between the P2X4R and β-adrenergic receptor ([@B36]). Taken together, the expression of both P2X7Rs and P2X4Rs in salivary glands supports the idea that they are involved in the interplay between canonical and non-canonical signaling pathways that regulate saliva flow and composition and their involvement is likely dependent on their tissue localization (i.e., basal vs. apical) in polarized acinar and/or ductal epithelial cells ([@B31], [@B30]).

The metabotropic P2Y~1~ receptor (P2Y~1~R), formerly known as the P~2T~ receptor, has been identified and cloned ([@B333]; [@B26]) and has features typical of G protein-coupled receptors, i.e., an extracellular N-terminus and an intracellular C-terminus, seven hydrophobic transmembrane regions, three extracellular loops and three intracellular loops ([@B328]). The P2Y~1~R has a distinctive rank order of agonist potencies (i.e., 2-methylthio-ADP \> ADP \> ATP) and its activation induces canonical Gα~q~ signaling leading to phospholipase C activation and generation of the second messengers inositol 1, 4, 5-trisphosphate (IP~3~) and diacylglycerol that increase \[Ca^2+^\]~i~ and protein kinase C (PKC) activity, respectively ([@B330]; [@B1]; [@B26]; [@B327]). Additionally, P2Y~1~R activation stimulates metalloprotease-dependent transactivation of the epidermal growth factor receptor (EGFR) ([@B45]) and mitogen-activated protein kinase (MAPK) activity through activation of phosphatidylinositol 3-kinase, Src kinase and PKC ([@B275]; [@B26]). The P2Y~1~R is widely distributed in mammalian tissues and is involved in many physiological and biochemical responses, such as platelet aggregation ([@B95]), pain sensation ([@B27]), vasodilation ([@B355]), bone remodeling ([@B235]), and osmotic volume regulation ([@B112]). In exocrine tissues, immunofluorescence and RT-PCR analyses provide evidence of P2Y~1~R expression in pancreatic ductal cells where P2Y~1~R agonists also induce \[Ca^2+^\]~i~ increases ([@B183]; [@B67]). However, the role of P2Y~1~Rs in exocrine pancreas function has been unexplored. Likewise, P2Y~1~R expression has been demonstrated in lacrimal acinar cells and myoepithelial cells by RT-PCR, immunofluorescence and measurement of P2Y~1~R agonist-induced \[Ca^2+^\]~i~ increases, but further functional analyses are lacking ([@B233]). Interestingly, the P2Y~1~R has been used as a surrogate cell-surface marker for the nuclear protein pancreatic duodenal homeobox 1 (PDX1) to isolate progenitor-like ductal cells from human pancreatic tissues, although no functional role for P2Y~1~Rs was investigated ([@B256]). In contrast, studies on endocrine pancreas function suggest a role for P2Y~1~Rs in mediating insulin secretion from β cells ([@B169]; [@B247]). The P2Y~1~R is also involved in tissue development, as was first described in chick embryos ([@B200]; [@B201]) and more recently in the developing brain ([@B127]). In the developing rat salivary gland, it was observed that acinar cells prepared from immature glands of 1 day-old pups had a robust \[Ca^2+^\]~i~ response to P2Y~1~R agonists, whereas acini prepared from adult rat salivary glands had no response ([@B240]). Interestingly, P2Y~1~R mRNA expression remained the same at all ages in rats, suggesting that the loss of the P2Y~1~R-mediated \[Ca^2+^\]~i~ response may be due to age-dependent alterations in intracellular G protein coupling ([@B240]). A subsequent study using rat SMG acinar and ductal cell preparations confirmed the age-dependent reduction in P2Y~1~R-mediated increases in \[Ca^2+^\]~i~ and, similarly, found unchanged P2Y~1~R expression levels at all ages ([@B21]). This study further demonstrated that P2Y~1~R-mediated activation of the MAPKs, extracellular signal-regulated kinases 1 and 2 (ERK1/2), was consistent in rats of all ages, indicating that ERK1/2 activation is independent of P2Y~1~R-mediated changes in \[Ca^2+^\]~i~. Western analysis and assays of GTPγ^35^S binding to G proteins determined that the age-dependent decrease in P2Y~1~R activity in rat SMG cells was due to both decreased expression of the 52 kDa Gα~14~ protein and differential coupling of P2Y~1~Rs to Gα~q/11~ with age ([@B21]). These studies suggest that P2Y~1~Rs use diverse mechanisms for coupling to multiple G proteins that regulate a variety of physiological responses during development. To date, these findings have not been confirmed in salivary glands of mice, but with the availability of P2Y~1~R-null mice, it would be of interest to assess the role of this receptor in salivary gland morphology and function during development.

The P2Y~2~R (formerly known as the P~2U~ receptor), equipotently activated by ATP or UTP (EC~50~ ∼ 2 μM), is the only other known Gα~q~-coupled purinergic receptor identified in salivary glands ([@B322], [@B320]) and has been cloned and functionally characterized in mice and humans ([@B93]; [@B184]; [@B241]). Similar to the P2Y~1~R, P2Y~2~R activation induces canonical Gα~q~ signaling leading to increases in \[Ca^2+^\]~i~ and PKC activation, and the P2Y~2~R is expressed in numerous cell and tissue types, e.g., neurons ([@B246]), epithelium ([@B288]; [@B346]), endothelium ([@B280]) and immune cells ([@B138]; [@B345]), where it modulates a variety of cellular responses, including neurotransmission ([@B356]), proliferation ([@B281]), cell migration ([@B20]), cytoskeletal rearrangements ([@B173]), and ion fluxes ([@B211]). The diversity of cellular responses mediated by P2Y~2~Rs is due, in part, to unique structural features enabling activation of multiple signal transduction pathways. In addition to canonical Gα~q~ signaling ([@B241]), the P2Y~2~R contains a motif typically found in extracellular matrix proteins, i.e., an Arg-Gly-Asp (RGD)-sequence, in its first extracellular loop that binds to α~v~β~3~/β~5~ integrins to activate G~o~ and G~12~ proteins, enhance MAPK (ERK1/2) phosphorylation and regulate ATP- and UTP-induced cell chemokinesis and chemotaxis ([@B92]; [@B20]; [@B331]; [@B173]). Within the intracellular C-terminus of the P2Y~2~R, Src-homology-3 (SH3) binding domains (PXXP) enable the P2Y~2~R to bind and activate the tyrosine kinase Src, enabling nucleotide-induced, Src-dependent transactivation of growth factor receptors and downstream MAPKs that regulate cell proliferation and migration ([@B176]; [@B279]). Additionally, interaction of the P2Y~2~R C-terminus with the actin-binding protein filamin-A contributes to cell migration and Rho GTPase-mediated cytokine release ([@B351]; [@B276]). The P2Y~2~R also mediates the proprotein convertase furin-dependent activation of metalloproteases, i.e., a disintegrin and metalloproteinase 10 and 17 (ADAM10/17), to cleave transmembrane proteins ([@B46]), thereby releasing EGFR/ERB ligands that promote Src-independent EGFR activation ([@B263]). These diverse P2Y~2~R signaling pathways have been implicated in a number of pathologies, including Alzheimer's disease ([@B7]), cardiovascular disease ([@B57]), cancer ([@B125]), SS ([@B345]), and hantavirus cardiopulmonary syndrome ([@B33]), as well as processes such as wound healing ([@B144]) and tissue regeneration ([@B89]).

In exocrine tissues such as the lacrimal gland, RT-PCR and immunohistochemical analyses have identified P2Y~2~R expression in acinar and ductal cells ([@B149]; [@B309]). While no functional response to the P2Y~2~R agonist UTP was observed in lacrimal acinar cells ([@B149]), cultured lacrimal gland myoepithelial cells do exhibit increased \[Ca^2+^\]~i~ in response to extracellular UTP suggesting the presence of P2Y~2~ or P2Y~4~ receptors ([@B233]). In the exocrine pancreas, RT-PCR and immunohistochemical analyses indicate that P2Y~2~Rs are expressed in both pancreatic acini ([@B228]) and ductal cells ([@B117]; [@B183]; [@B67]), although very few pancreatic acinar cells show functional responses to extracellular ATP or UTP ([@B228]). In pancreatic ductal cells, P2Y~2~R-mediated increases in \[Ca^2+^\]~i~ altered whole-cell K^+^ conductance ([@B117]), likely through modulation of Ca^2+^-activated K^+^ channels ([@B118]), suggesting a role in the regulation of ductal fluid flow and Cl^--^/HCO$_{3}^{-}$ levels. Studies with pancreatic ductal cell lines have also shown that the P2Y~2~R agonists ATP and UTP increase membrane Cl^--^ conductance through the opening of Ca^2+^-dependent Cl^--^ channels ([@B103]; [@B53]; [@B360]). The ability of P2Y~2~Rs to induce chloride secretion and subsequent fluid flow across epithelial cell membranes led to investigation of the P2Y~2~R as a therapeutic target for cystic fibrosis ([@B338]; [@B151]; [@B164]). By stimulating Ca^2+^-dependent Cl^--^ secretion, topical application of the selective P2Y~2~R agonist diquafosol has been shown to promote tear secretion and is currently being used to treat DED ([@B141]).

In 1991, the P2Y~2~R was first identified in a cell line of salivary gland origin, human salivary gland (HSG) cells, where it was shown to mediate UTP-induced IP~3~ production and increases in \[Ca^2+^\]~i~ and plasma membrane K^+^ transport ([@B350]). A subsequent study determined that exposure of HSG cells to UTP potentiated a regulatory volume decrease (RVD) after hypotonic stress, suggesting that activation of P2Y~2~Rs provides the driving force for net Cl^--^ efflux that enables the cells to rapidly restore their volume ([@B155]), a response that occurs during salivary secretion ([@B198]). In 1998, it was shown that simian virus 40-transformed salivary cell lines from rat SMG and parotid glands ([@B259]), unlike HSG cells, were suitable for Ussing chamber studies due to their ability to form polarized cell monolayers ([@B321]). Using the polarized rat parotid cell line Par-C10 in a Ussing chamber, transepithelial resistance measurements determined that functional P2Y~2~R expression was localized to the apical membrane, consistent with its localization in other epithelium ([@B136]; [@B54]; [@B347]), and its activation by UTP increased an anion ($\text{Cl}^{-}/\text{HCO}_{3}^{-}$)-dependent change in short-circuit current (I~sc~) ([@B53], [@B54]; [@B63]). Taken together, these results suggest that expression of P2Y~2~Rs on salivary gland epithelium may contribute to saliva secretion; however, subsequent studies with freshly isolated salivary acinar cells showed little evidence of P2Y~2~R expression or activity under steady-state conditions ([@B323]; [@B6]; [@B273]). Moreover, carbachol-stimulated whole saliva secretion in P2Y~2~R-null mice (P2Y~2~R^--/--^) is unchanged compared to wild type mice ([@B345]), suggesting that P2Y~2~Rs do not contribute to overall fluid secretion. Earlier studies demonstrated UTP-induced Cl^--^ fluxes in rat salivary duct cells ([@B166]; [@B354]) with one study suggesting that P2Y~2~R expression on striated ducts regulates CFTR activity ([@B140]), thereby possibly modifying the ionic content of saliva.

The Role of P2 Receptors in Salivary Gland Inflammation {#S3}
=======================================================

The contribution of P2 receptors to physiological salivary gland function is predicated on the presence of endogenous agonists (i.e., extracellular nucleotides) in sufficient concentrations to activate their cognate receptors, as is the case when ATP is co-released with neurotransmitters from sympathetic and parasympathetic nerves ([@B329]; [@B225]). In exocrine tissues such as the pancreas and lacrimal glands, ATP is released in response to stimulation by physiological agonists such as acetylcholine and cholecystokinin-8 ([@B294]; [@B348]; [@B227]; [@B71]). Additionally, measurable amounts of ATP are present in rat saliva induced by intraperitoneal pilocarpine administration ([@B140]). However, the concentration of extracellular nucleotides is tightly regulated under physiological conditions and maintained in the low μM range by ectonucleotidases ([@B244]; [@B82]), such as the nucleoside triphosphate diphosphohydrolase ENTPD1 (CD39) and related family members ([@B78]; [@B359]). Using conventional luciferin/luciferase luminescence measurements or cell-based biosensors, the concentration of extracellular ATP released from pancreatic acinar or β cells has been measured at ∼10--25 μM ([@B116]; [@B294]), although *in vivo* measurement of absolute extracellular nucleotide concentrations is an active area of research ([@B76]). However, during periods of inflammation or other cellular stresses, such as hypoxia in the tumor microenvironment, extracellular ATP levels have been shown to exceed 100 μM and are likely much higher in the context of the confined pericellular space ([@B244]; [@B145]; [@B82]; [@B77]). Immune and apoptotic cells release ATP through connexin and pannexin hemichannels during inflammatory responses and uncontrolled release of intracellular ATP pools can also occur during cell necrosis ([@B90]; [@B56]). Mounting evidence also suggests that connexin 43-mediated ATP release from γ-irradiated cells causes the radiation-induced bystander effect where adjacent, non-irradiated cells exhibit physiological responses mediated by P2 receptors ([@B316]; [@B231]; [@B315]; [@B160]). Interestingly, the ionotropic P2X7 receptor also has been shown to mediate ATP release ([@B296]; [@B232]), likely through its sustained activation that leads to membrane depolarization and pore formation ([@B68]; [@B336]; [@B38]), and P2X7R blockade has been shown to attenuate ionizing radiation (IR)-induced ATP release from salivary acinar cells ([@B107]). Recognizing that salivary gland inflammation and radiation exposure, two common sources of salivary gland dysfunction, promote the release of extracellular nucleotides and subsequent P2 receptor activation, defining the role of P2 receptors in salivary gland pathophysiology has been an area of intense interest.

In addition to its role as an ion channel, activation of the P2X7R initiates signaling cascades that produce pro-inflammatory cytokines (e.g., IL-1β, IL-18, IL-6, IL-8, and TNF-α) to enable antigen-presenting cells to initiate innate immune responses ([@B98]; [@B292]; [@B196]; [@B175]; [@B286]). In salivary epithelium, our group has shown that P2X7R activation with ATP or BzATP triggers apoptotic and pro-inflammatory cell responses, including increases in caspase-1 and caspase-3 activity and immune cell infiltration into wild type, but not P2X7R^--/--^, mouse SMGs ([@B343]). Also, P2X7R activation in salivary epithelium was found to induce the assembly of the NLRP3 inflammasome multiprotein complex and the subsequent release of IL-1β, a response that was dependent on K^+^ efflux, production of ROS and functional heat shock protein 90 ([@B154]). P2X7R activation also has been shown to mediate the protease-dependent release of α-fodrin ([@B343]), a putative autoantigen associated with SS ([@B204]), through a mechanism that requires caspase-3 and calpain enzymatic activities ([@B135]). P2X7R activation induces membrane blebbing, an early indicator of cell apoptosis, in salivary epithelial cells isolated from wild type, but not P2X7R^--/--^, mice ([@B343]). The mechanism of P2X7R-mediated membrane blebbing was shown to require sustained elevation of \[Ca^2+^\]~i~, activation of the ROCK I signaling pathway and phosphorylation of myosin light chain, but does not involve caspase-3 activation ([@B134]).

There are increasing lines of evidence that P2X7R-induced pro-inflammatory responses are modulated by the P2X4R as well. In immune cells, P2X4Rs have been shown to modulate P2X7R-induced IL-1β release and dye uptake through interaction with the P2X7R C-terminus and P2X4R antagonism abolished P2X7R-induced Ca^2+^ influx and IL-1β and IL-18 release ([@B270]). In gingival epithelial cells, P2X7Rs, P2X4Rs and pannexin-1 hemichannels were all required for ATP-induced ROS production, NLRP3 inflammasome activation and IL-1β release ([@B131]). These cellular mechanisms may also be important in IL-1β release from salivary epithelium, where P2X4Rs have been shown to modulate P2X7R-mediated ion flow and pore formation ([@B50]).

In rodent salivary glands, P2Y~2~R expression is negligible under physiological conditions. Interestingly, freshly dispersed salivary epithelial cells significantly upregulated P2Y~2~R expression and activity as a function of time when placed in culture ([@B323]; [@B89]), consistent with a possible role for P2Y~2~R in the cellular response to stress. P2Y~2~R upregulation also occurs in the *in vivo* ductal ligation model of salivary gland inflammation and fibrosis ([@B6]) and has been similarly seen in other *in vivo* models of stress and inflammation, i.e., intestinal inflammation ([@B110]), rat vascular neointima formation after balloon angioplasty ([@B277]), collared rabbit carotid arteries ([@B278]), glomerulonephritis ([@B264]), myocardium of rats with congestive heart failure ([@B109]) and mouse models of the autoimmune disease SS ([@B273]; [@B345]). IL-1β has been previously shown to induce P2Y~2~R upregulation ([@B161]; [@B246]), likely through binding of NF-κB p65 to the *P2Y~2~R* promoter region that has been demonstrated to mediate inflammation-induced P2Y~2~R upregulation in human intestinal epithelial cells ([@B79]). Taken together, these studies suggest that ATP released from stressed cells during inflammation activates P2X7Rs to induce the release of IL-1β and other cytokines. Subsequent activation of IL-1 receptors by IL-1β in surrounding cells induces P2Y~2~R upregulation and further downstream responses to ATP and UTP. In this way, the release of a single alarmin (e.g., ATP or UTP) in response to cellular stress can locally modulate a wide range of signaling pathways to fine-tune the tissue response to inflammatory stimuli.

In HSG cells, UTP-induced activation of P2Y~2~Rs has been shown to regulate localized immune responses and the binding of immune cells through the upregulation of the cell adhesion molecule VCAM-1 via an EGFR-dependent mechanism ([@B22]). Furthermore, P2Y~2~R activation has been shown to stimulate the production and secretion of pro-inflammatory lymphotoxin-α (LT-α), a member of the tumor necrosis factor family of cytokines that is required for the development of lymphoid tissues and mediates interactions between immune cells ([@B284], [@B283]), suggesting multiple mechanisms whereby P2Y~2~Rs regulate localized immune responses relevant to salivary gland inflammation ([@B276]; [@B257]; [@B345]).

P2 Receptors in Sjögren's Syndrome {#S4}
==================================

A number of autoimmune inflammatory diseases are reported to impact the function of salivary glands, including rheumatoid arthritis ([@B214]; [@B119]; [@B352]), systemic lupus erythematosus (SLE) ([@B168]) and diabetes mellitus ([@B207]). One of the major causes of salivary gland dysfunction is chronic inflammation associated with the autoimmune disease SS, the 2^nd^ most common autoimmune rheumatic disease in the U.S., in which unresolved inflammation of the salivary and lacrimal glands contributes to tissue degeneration and subsequent loss of function ([@B120]; [@B326]). Clinical classification criteria for primary SS (pSS) in the absence of other autoimmune diseases include the presence in blood serum of anti-Ro/SSA and anti-La/SSB autoantibodies to their intracellular antigens, increased corneal staining using fluorescein dye (ocular staining score ≥ 5), decreased tear (Schirmer's test ≤ 1 mm/min) and saliva (≤ 0.1 ml/min) flow rates and the presence of focal lymphocytic sialadenitis (focus score ≥ 1 foci/4 mm^2^) in minor salivary gland biopsies ([@B285]). During SS pathogenesis, T and B cells ([@B324]; [@B70]), dendritic cells ([@B238]; [@B357]), and macrophages ([@B188]) accumulate in the salivary glands where, along with salivary gland epithelial cells, they produce numerous pro-inflammatory cytokines, including IFN-γ, B cell-activating factor, TNF-α, IL-1β, IL-6 and IL-18, which initiate pro-inflammatory immune responses that ultimately degenerate the salivary glands ([@B129]; [@B340]; [@B69]; [@B268]; [@B219]). Additionally, SS patients produce high levels of immunoglobulins and autoantibodies besides anti-Ro/SSA and anti-La/SSB ([@B218]; [@B297]), including anti-α-fodrin ([@B332]; [@B204]), RF (rheumatoid factor) ([@B210]; [@B132]) and other autoantibodies ([@B261]; [@B282]; [@B297]) that have been previously reported to activate intrinsic and extrinsic apoptotic pathways in salivary gland cells ([@B290]; [@B174]). Furthermore, anti-muscarinic receptor-3 autoantibodies that inhibit saliva production and aquaporin translocation to the plasma membrane ([@B19]; [@B74]) have been identified in the blood serum of SS patients. Taken together, these data suggest that chronic auto-inflammatory responses along with autoantibody-induced reductions in saliva and tear production and increased salivary acinar cell apoptosis contribute to pSS pathogenesis that ultimately leads to salivary gland dysfunction and fibrosis as well as systemic pathologies (i.e., chronic fatigue, lymphoma development, and secondary autoimmune manifestations).

Previous studies have demonstrated that the expression of *P2X7R*, *caspase-1*, *IL-1β*, *IL-18* and components of the NLRP3 inflammasome multiprotein complex are significantly increased in labial salivary gland biopsies from SS patients, which positively correlates with salivary gland focus score (\# of mononuclear cell foci/4 mm^2^ tissue area) ([@B23], [@B24]). Furthermore, these studies found that when SS patients were stratified based on the presence of anti-Ro/SSA autoantibodies, the increased expression of *P2X7R* and NLRP3 inflammasome components was even more pronounced in seropositive cohorts compared to seronegative cohorts ([@B23], [@B24]). Subsequent immunofluorescence analysis indicated that P2X7R expression in SS salivary gland biopsies co-localized with the acinar epithelial cell marker aquaporin 5, rather than immune cell markers, suggesting that P2X7Rs on salivary gland epithelium contribute to SS pathogenesis through a process termed autoimmune epithelitis ([@B203]; [@B24]). Additionally, this prospective study of 147 SS patients over ∼5 years found that those who eventually developed mucosa-associated lymphoid tissue non-Hodgkin lymphoma (MALT NHL), a serious complication of SS, had significantly higher labial salivary gland *P2X7R* expression at the time of SS diagnosis compared to non-lymphoma SS patients, suggesting that P2X7R expression may be a useful biomarker for MALT NHL development ([@B24]). In an analysis of *P2X7R* functional polymorphisms in 114 SS patients and 136 non-SS controls, the frequency of a single nucleotide polymorphism in exon 13 (A1405G, rs2230912) was significantly increased in seropositive SS patients, as compared to control subjects ([@B170]). As determined by ATP-induced ethidium bromide uptake to detect P2X7R activation in isolated peripheral blood lymphocytes, the P2X7R A1405G polymorphism was found to be a gain-of-function mutation that was suggested to be a risk factor for seropositive SS in the absence of other SS-associated human leukocyte antigen risk alleles. However, this A1405G association failed to be replicated in a larger patient cohort ([@B170]).

Antagonism of the P2X7R, whose encoding gene is located within a mapped SLE susceptibility region on chromosome 12 ([@B88]), has been investigated as a potential treatment for several inflammatory diseases, including SLE ([@B319]; [@B311]), rheumatoid arthritis ([@B14]) and chronic obstructive pulmonary disease ([@B182]). Due to its increased expression in salivary gland biopsies from SS patients ([@B23]) and its reported role in the activation of pro-inflammatory responses in salivary epithelium ([@B343]), the P2X7R has emerged as an appealing therapeutic target to treat SS. Our group reported that *in vivo* inhibition of P2X7Rs using the competitive antagonist A-438079 significantly reduced sialadenitis and improved carbachol-induced saliva flow in the NOD.H-2^h4^, CD28^--/--^, IFNγ^--/--^ murine model of SS-like salivary gland autoimmune exocrinopathy ([@B154]). P2X7R antagonism also significantly reduced salivary gland expression of immunoactive molecules known to be upregulated in salivary gland biopsies isolated from SS patients, including IL-1β, ICAM, VCAM, E-selectin, CD80, and CD86 ([@B317]; [@B154]). Taken together, these studies suggest that the P2X7R represents a promising target for therapeutic intervention in salivary gland inflammation.

Previous studies have demonstrated that the P2Y~2~R is upregulated in major salivary glands of several mouse models of SS, including NOD.B10 ([@B273]), IL-14α transgenic (IL-14αTG) ([@B345]) and C57BL/6-NOD.*Aec1Aec2* mice (unpublished observations). It was recently reported by our group that P2Y~2~R expression was increased in both SMG epithelium and SMG-infiltrating B cells in aged IL-14αTG mice with SS-like disease and genetic deletion of the P2Y~2~R attenuated both B and T cell infiltration of the salivary glands ([@B345]). Additionally, attenuated sialadenitis following P2Y~2~R deletion correlated with significantly reduced levels of LT-α in salivary gland epithelial cells and infiltrating immune cells, suggesting that P2Y~2~R-mediated LT-α expression contributes to salivary gland inflammation in IL-14αTG mice ([@B345]). Interestingly, LT-α levels are increased in the saliva, serum and salivary glands of SS patients, as compared to healthy individuals ([@B284]; [@B312]), and blockade of the LT-α receptor has been shown to reduce sialadenitis and improve the secretory function of the salivary gland in the IL-14αTG and NOD mouse models of SS ([@B105]; [@B283]). Lastly, unpublished observations from our lab indicate that expression of the *P2Y~2~R* is increased in salivary gland-infiltrating B cells in NOD.H-2^h4^, CD28^--/--^, IFNγ^--/--^ mice, as compared to B cells isolated from salivary glands of C57BL/6 control mice, and intraperitoneal administration of the selective P2Y~2~R antagonist AR-C118925 significantly attenuates sialadenitis and restores salivary gland function. In summary, these studies highlight the significant contributions of purinergic receptors to salivary gland inflammation and demonstrate their therapeutic potential for the treatment of human pro-inflammatory autoimmune diseases.

P2 Receptors in Radiation-Induced Hyposalivation {#S5}
================================================

Radiation-induced salivary gland dysfunction is a common unintended side effect of radiotherapy in head and neck cancer patients, which causes xerostomia and hyposalivation that affects \> 95% of these patients, \> 73% of whom continue to suffer from months to years after completion of the radiotherapy ([@B243]; [@B83]; [@B143]; [@B250]). Head and neck cancer patients routinely receive fractionated radiation treatment where the tumor region receives high radiation doses while salivary gland sparing techniques attempt to limit the radiation dose to 2 Gy/day ([@B85]; [@B113]; [@B248]). It is estimated that the tolerance dose for a 50% complications rate (TD50) for the parotid and submandibular glands is 28.4 and 39 Gy, respectively ([@B85]; [@B172]; [@B212]). A number of factors including tumor grade, lymph node involvement and location of the tumor create scenarios where salivary gland sparing is not feasible and the tissue is exposed to higher radiation doses. Consequently, chronic hyposalivation and changes in the saliva electrolyte composition occur along with a reduction in pH that leads to alterations in oral microbial flora, increased incidence of dental carries and oral infections and difficulties with swallowing, digestion, and speech ([@B126]; [@B250]).

Several groups have utilized rodent models to demonstrate that acute hyposalivation occurs immediately after IR, before the onset of overt gland damage, which is associated with sustained increases in the \[Ca^2+^\]~i~ ([@B64]; [@B177], [@B178]; [@B10]). In contrast, chronic IR-induced salivary dysfunction results from ROS production, increased caspase-3 activity, disruption of store-operated Ca^2+^ entry (SOCE), cytoskeletal rearrangements, acinar cell apoptosis, sialadenitis and replacement of normal parenchyma with fibrotic tissue ([@B66]; [@B260]; [@B313]; [@B209]; [@B18]; [@B177], [@B178]; [@B342]). One of the early responses to IR is impairment of muscarinic receptor signaling ([@B65], [@B64]; [@B162]) required for saliva formation and aquaporin channel activity required for fluid secretion ([@B301]). Furthermore, [@B18], have demonstrated that radiation also causes a significant reduction in saliva-secreting acinar cells due to p53-dependent apoptosis. Thus, the overall mechanism of radiation-induced salivary gland hypofunction likely involves perturbations in muscarinic receptor signaling, apoptosis of saliva-producing acinar cells and irreversible tissue damage.

The P2X7R is highly expressed in salivary epithelium where its activation induces responses associated with IR-induced hyposalivation, including ROS production, caspase-3 activity, prostaglandin E~2~ and ATP release, NLRP3 inflammasome activation with IL-1β release and salivary gland cell apoptosis ([@B343]; [@B154]; [@B107]). Thus, we recently explored the role of P2X7R activation in γ-radiation-induced hyposalivation. IR exposure induced ATP release from wild type mouse parotid gland epithelial cells (PGECs) that was attenuated by the P2X7R antagonist A-438079 and in PGECs isolated from P2X7R^--/--^ compared to wild type mice ([@B107]). Furthermore, systemic administration of A-438079 in γ-irradiated wild type mice conferred significant radioprotection to salivary glands and maintained saliva flow rates similar to non-irradiated mice at 3 and 30 days post-IR. This study also demonstrated that PGE~2~ is secreted from wild type PGECs following γ-radiation that was reduced in P2X7R^--/--^ PGECs or following A-438079 pretreatment of wild type PGECs ([@B107]). Prostaglandins modulate inflammatory responses by altering cytokine production and secretion in macrophages ([@B266]; [@B13]). The signaling pathway downstream of cyclooxygenase-2 (COX-2), the rate-limiting enzyme that converts arachidonic acid into prostaglandins ([@B55]), has been shown to contribute to the IR-induced bystander effect in other cell types ([@B358]; [@B51]; [@B158]) and P2X7R activation has been shown to induce arachidonic acid release from rat SMG ductal cells ([@B9]). These findings suggest that P2X7R antagonists provide radioprotection by attenuating the damaging tissue response to IR-induced release of alarmins, including ATP and PGE~2~.

P2 Receptors in Salivary Gland Regeneration {#S6}
===========================================

While most current treatments for salivary gland dysfunction target expansion of residual salivary acinar cells to repair damaged tissue, regenerative therapy with stem cells is a novel and promising therapeutic approach to replace damaged salivary glands ([@B48]; [@B180]; [@B230]). Several studies have identified and characterized subsets of endogenous salivary progenitor cells that can be exploited to promote tissue regeneration ([@B181]; [@B58], [@B59]; [@B254]; [@B91]; [@B339]). The use of modified fibrin hydrogels ([@B216]), layered sheets of isolated salivary gland cells released from thermoresponsive culture dishes ([@B217]) and salivary organoid cultures generated from embryonic pluripotent stem cells ([@B307]) have been explored as regenerative therapies for damaged salivary glands. Tissue engineering of 3-dimensional (3-D) primary HSG cultures for transplantation into afflicted patients represents another regenerative strategy to restore salivary gland function ([@B180]). Because primary human salivary gland cells undergo loss of cell-specific protein expression and biological function when cultured in a monolayer ([@B142]), development of 3-D culture strategies using Matrigel ([@B96]; [@B189]), collagen-Matrigel ([@B146]; [@B254]), hyaluronic acid-based hydrogels ([@B253]) and magnetic 3-D levitation ([@B99]) has been explored to maintain salivary gland cell function in culture. Indeed, transplantation of 3-D cultured, primary human salivary gland cells has been shown to ameliorate radiation-induced salivary gland dysfunction in mice ([@B254]).

Rodent salivary glands have been shown to possess a high capacity to regenerate following the ligation or obstruction of the main excretory ducts of the gland, where ligated salivary glands initially become inflamed before glandular atrophy occurs through TGF-β-induced fibrosis and Fas ligand-induced epithelial cell apoptosis ([@B39]; [@B6]; [@B305], [@B303], [@B302]; [@B49]; [@B344]). Following de-ligation, residual cells in damaged salivary glands can regenerate the gland through proliferation, migration and self-organization ([@B304]; [@B187]; [@B156]; [@B16]), thereby restoring salivary gland function, i.e., increasing the secretion rate of saliva with a normal ion and protein composition ([@B274]; [@B237]). Concurrent with these glandular changes, functional P2Y~2~R expression, which is very low under homeostatic conditions, is robustly increased in salivary epithelial cells in response to ductal ligation and P2Y~2~R expression returns to basal low levels following de-ligation and subsequent recovery of the salivary gland ([@B6]; [@B89]). These findings are in agreement with previous studies demonstrating P2Y~2~R upregulation in epithelial cells in response to tissue damage and inflammation ([@B323]; [@B273]; [@B79]; [@B345]), suggesting that the P2Y~2~R is an important component in the repair and regeneration of damaged salivary glands.

Previous studies have demonstrated a role for the P2Y~2~R in corneal epithelial wound healing by increasing cell migration ([@B34]), in liver regeneration by stimulating hepatocyte proliferation ([@B300]), in cardiac regeneration by stimulating cardiac progenitor cell proliferation ([@B153]) and in intestinal epithelial cell tubulogenesis ([@B137]). Activation of P2Y~2~Rs in the HSG cell line also induces the transactivation, homodimerization and autophosphorylation of the EGFR, a receptor tyrosine kinase known to be crucial for salivary gland branching morphogenesis and development ([@B205]; [@B242]; [@B206]). This process in salivary epithelial and endothelial cells involves ADAM10/17-dependent proteolytic cleavage induced by P2Y~2~R activation that causes the release of cell surface-bound EGFR ligands as well as the Src kinase-dependent transactivation of growth factor receptors through the binding of Src to SH3 binding motifs in the P2Y~2~R intracellular domain ([@B176]; [@B279]; [@B263]). In HSG cells, P2Y~2~R activation also induces the heterodimerization of EGFR and ErbB3, another member of the EGFR family ([@B263]). ErbB3 has an inactive kinase domain that requires heterodimerization with EGFR to respond to its ligand, neuregulin, which then stimulates the ERK/MAPK signaling pathway to promote cell proliferation, migration, and differentiation ([@B242]; [@B263]).

Integrins are transmembrane cell surface receptors that interact with extracellular matrix components, including laminin ([@B222]), fibronectin ([@B28]) and collagen ([@B318]), intracellular cytoskeletal proteins and other cell surface receptors ([@B167]) that are crucial components in the salivary gland regeneration process ([@B334]; [@B89]). Hence, the bi-directional nature of integrin signaling regulates many physiological processes relevant to salivary gland regeneration, including cell proliferation, polarity, migration, and adhesion ([@B167]). Through its extracellular RGD domain, the P2Y~2~R can bind directly to integrins (e.g., α~v~β~*3/5*~) and allow for nucleotide-induced P2Y~2~R-mediated activation of integrin signaling pathways, including Rho and Rac GTPase activation that regulate cytoskeletal rearrangements ([@B92]; [@B331]). The extracellular ligand for the α~5~β~1~ integrin is fibronectin, a well-known mediator of salivary gland morphogenesis ([@B269]; [@B234]), and we have previously demonstrated that UTP-induced P2Y~2~R activation also induces α~5~β~1~ integrin-mediated migration, aggregation, and self-organization of dispersed salivary epithelial cells into acinar-like spheres ([@B89]). These spheres resemble native acinar units of the salivary gland, possessing a lumen and organized expression of the tight junction protein ZO-1, and we have shown that the mechanism for P2Y~2~R-mediated self-organization of salivary gland cells involves the activation of EGFR via the Cdc42 Rho GTPase pathway and subsequent downstream activation of ERK1/2 and JNK signaling pathways ([@B89]). Thus, these studies suggest a promising role for unique structural motifs in P2Y~2~Rs that are highly relevant to cell-based regenerative therapy and bioengineering of salivary glands.

Summary {#S7}
=======

Activation of purinergic receptors for extracellular nucleotides in the salivary glands modulates various physiological and pathophysiological functions ([Table 1](#T1){ref-type="table"}). The ATP-gated ionotropic P2X7 receptor in salivary acinar cells contributes to physiological salivary gland function by modulating muscarinic receptor-induced saliva secretion into the ductal lumen, whereas activation of ductal P2X7Rs modulates ion and protein content of saliva. P2X4R activation also contributes to saliva secretion through the formation of functional homotrimers and P2X4R/P2X7R heterotrimers in salivary gland epithelium, suggesting that P2XRs represent an integration point between canonical and non-canonical signaling pathways that regulate saliva flow and composition. P2Y~1~Rs also may contribute to salivary gland development through coupling to multiple G proteins resulting in diverse physiological responses. The ability of P2Y~2~R activation to stimulate increases in \[Ca^2+^\]~i~ and Cl^--^ flow across epithelial membranes suggests a role in saliva secretion, however, P2Y~2~R expression is negligible under normal steady-state conditions. The observed upregulation of P2Y~2~R expression during tissue stress and in response to P2X7R-induced IL-1β release suggest their significant role in salivary gland pathophysiology. Due to an increase in extracellular nucleotide release during tissue inflammation and dysregulation, nucleotide-induced activation of the interconnected P2X7R-P2Y~2~R signaling pathways likely modulates multiple immunological and tissue repair functions, including cell migration, growth factor receptor transactivation, integrin signaling, adhesion molecule upregulation, and cytokine release. Thus, P2X7R activation in salivary epithelium and upregulation of the P2Y~2~R with its unique structural domains likely regulate both salivary gland dysfunction and repair through the stimulation of these important pro-inflammatory processes.

###### 

Expression and function of purinergic receptors in salivary glands.

  Purinergic receptor   Cell or tissue type                           Salivary gland function                                                                                                                          References
  --------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------
  P2X7                  Rat parotid acinar cells                      Mediates eATP-induced Ca^2+^ entry                                                                                                               [@B293]; [@B80]; [@B194], [@B195]
                                                                      Mediates eATP-induced plasma membrane permeabilization and large pore formation                                                                  [@B106]
                        Rat submandibular acinar cells                Induces plasma membrane permeabilization and large pore formation                                                                                [@B8]
                                                                      Inhibits carbachol- and substance P-induced mobilization of intracellular Ca^2+^                                                                 [@B133]; [@B199]
                                                                      Increases phospholipase A2-dependent secretion of arachidonic acid and kallikrein                                                                [@B9]
                        Rat submandibular acinar and ductal cells     Mediates eATP-induced Ca^2+^ entry and increases membrane Cl^--^ conductance                                                                     [@B166]
                        Mouse parotid acinar cells                    Modulates carbachol-induced Ca^2+^ mobilization                                                                                                  [@B227]
                                                                      Mediates eATP-induced Ca^2+^ entry, Ca^2+^-induced Ca^2+^ release, and exocytosis                                                                [@B30], [@B31]
                                                                      Mediates eATP-induced membrane anion conductance                                                                                                 [@B265]
                        Mouse parotid acinar and ductal cells         Mediates eATP-induced Ca^2+^ entry and membrane conductance; cell-specific channel assembly properties                                           [@B171]
                                                                      Mediates γ-radiation induced eATP and PGE~2~ release                                                                                             [@B107]
                        Mouse submandibular acinar and ductal cells   Mediates eATP-induced apoptosis, ROS production, NLRP3 inflammasome assembly and IL-1β release                                                   [@B343]; [@B154]
                        *Ex vivo* mouse submandibular gland           Mediates eATP-induced fluid secretion and inhibits carbachol-induced fluid secretion                                                             [@B215]
                        *In vivo* mouse salivary glands               Modulates carbachol-induced saliva secretion                                                                                                     [@B251]; [@B227]
                                                                                                                                                                                                                       
  P2X4                  Rat parotid acinar cells                      Mediates eATP-induced Ca^2+^ entry                                                                                                               [@B194]
                        Mouse parotid acinar cells                    Mediates eATP-induced Ca^2+^ entry and exocytosis; potentiated by increased cAMP levels                                                          [@B31]; [@B30]
                                                                      Mediates eATP-activated membrane currents; functional interaction with P2X7 receptor                                                             [@B50]
                        Mouse submandibular ductal cells              Mediates eATP-induced Ca^2+^ entry                                                                                                               [@B251]
                        Human parotid acinar cells                    Mediates eATP-induced Ca^2+^ entry; potentiated by increased cAMP levels                                                                         [@B36]
                                                                                                                                                                                                                       
  P2Y~1~                Rat submandibular acinar and ductal cells     Mediates nucleotide-induced \[Ca^2+^\]~i~ increase; decreased activity in aged animals                                                           [@B240]
                                                                      Mediates nucleotide-induced \[Ca^2+^\]~i~ increase and ERK1/2 phosphorylation; differential coupling to Gα~14~ and Gα~q/11~ during development   [@B21]
                                                                                                                                                                                                                       
  P2Y~2~                Rat parotid cell line ParC10                  Mediates eUTP-induced increase in short-circuit current and Cl^--^ efflux                                                                        [@B321]
                        Rat submandibular acinar and ductal cells     Mediates eUTP-induced increase in membrane Cl^--^ conductance                                                                                    [@B166]; [@B354]
                                                                      Increased expression and eUTP-induced \[Ca^2+^\]~i~ increase during short-term culture                                                           [@B323]
                        *In vivo* rat submandibular glands            Increases CFTR-mediated Cl^--^ reabsorption to modify saliva ion content                                                                         [@B140]
                        Mouse submandibular acinar and ductal cells   Mediates eUTP-induced cell aggregation and migration through EGFR transactivation                                                                [@B89]
                        *In vivo* mouse submandibular glands          Increased expression and eUTP-induced \[Ca^2+^\]~i~ increase during salivary gland inflammation                                                  [@B273]; [@B6]; [@B345]
                        Human salivary gland (HSG) cell line          Mediates UTP-induced IP~3~ production, \[Ca^2+^\]~i~ increase and K^+^ efflux                                                                    [@B350]
                                                                      Potentiates cell regulatory volume decrease in response to hypotonic stress                                                                      [@B155]
                                                                      Increases vascular cell adhesion molecule expression                                                                                             [@B22]
                                                                      Mediates eUTP-induced EGFR phosphorylation and induces EGFR and ErbB3 heterodimerization                                                         [@B263]

eATP, extracellular ATP; eUTP, extracellular UTP; PGE

2

, prostaglandin E

2

; CFTR, cystic fibrosis transmembrane conductance regulator; EGFR, epidermal growth factor receptor.

In conclusion, purinergic receptors have emerged as promising therapeutic targets to promote physiological saliva flow, prevent salivary gland inflammation and enhance tissue regeneration required to reverse common causes of salivary gland dysfunction in humans, such as the autoimmune disease SS or the side effect of radiotherapy in head and neck cancer patients. Because purinergic receptors share common agonists and form heteromeric receptors with distinct pharmacologic profiles, unraveling the contribution of intracellular P2 receptor cross-talk to salivary gland dysfunction in animal models and humans will further define their therapeutic value in the treatment of salivary gland disorders. The continued development of high affinity P2R agonists and antagonists and the investigation of their safety and efficacy represent the next steps in the clinical translation of this promising P2 receptor research.
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